Granular Therapeutics Limited
- Small
- Active
- 8 years
- 4 employees
- £1,100,020 (assets)
- Real address
- 1 director
- No owners
- Irregular importer
Two conditions of three:
1.Turnover < £10.2 million
2.Balance sheet total < £5.1 million
3.Average number of employees < 50
Field of Operation
Website
Social media
Summary
Granular Therapeutics Ltd from Sandwich UK: small company, active status, founded 8 years ago, 4 employees, £1,100,020 assets, real address, 1 director, no owners. Irregular importer of pharmaceutical products (1 months imported). It’s a small company as it met two conditions of three: turnover less than £10.2 million, balance sheet less than £5.1 million, employees less than 50. The company operates in the research and experimental development on biotechnology industries. Officially, it has not published owners as their shares less than twenty five percent for each shareholder.
The company’s website, granulartherapeutics.com, states it’s “shaping the future of granulocytetargeted therapy in chronic inflammatory diseases.” More notably, it reveals Granular Therapeutics is now a fully owned subsidiary of Alys Pharmaceuticals, suggesting a significant shift in ownership and strategic direction. This transition likely explains the company’s reduced profile and irregular import activity.
Financially, Granular Therapeutics Ltd presents a mixed picture. While current assets remain at £1,100,000, a significant drop in cash reserves—down 82% to £250,000—is concerning. Net losses deepened considerably, increasing 180% to -£4,500,000, and equity plummeted 340% to -£7,900,000. Creditors have risen sharply, increasing 490% to £1,600,000, while staff costs have decreased slightly. The company’s small size (meeting two of three criteria for turnover under £10.2m, assets under £5.1m, and fewer than 50 employees) helps it stay agile, but the substantial losses and rising debt suggest it's burning through money. With no auditor mentioned (likely exempt as a small company), the figures rely on unaudited statements. The company’s parent company, Alys Pharmaceuticals, may be providing financial support, but the trend indicates a need for careful management and a clear path to profitability.
Registered in England/Wales under the registration number 10650696, with a registered address at CT13 9FF, United Kingdom, Sandwich, Kent, C/O Kreston Reeves Llp Innovation House, Ramsgate Road.
WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.
Managers
-
Individual
- 2 years
- 3
-
Resident of Switzerland
Last reports
The latest confirmation statement submitted four months ago.
Last news
-
Statement of capital following an allotment of shares on 2025-01-14Download 3 pages pdf report
-
Confirmation statement made on 2025-01-21 with updatesDownload 5 pages pdf report
-
Statement of capital on 2024-12-31Download 3 pages pdf report
Importer profile by HS codes
Click on the map to see detailed UK statistics on HS code, including companies list.
Last imported products
Click on items to see detailed UK statistics on HS code, including companies list.
Similar importers
- Company names
- HS codes
- Financial data
- Officers and owners
FAQ about Granular Therapeutics Limited
Looking for leads in the UK?
Try our FREE App—access UK datasets with limited features!